Fundraising Fox
/People
Sign in

Ben Scruggs

Investor

Principal at Hatteras Venture Partners · Manager at L2 Ventures

Raleigh-Durham / Southeast US

Writes $100K – $5M checks · typically $1.5M

Find your path to Ben

279 people in our graph can introduce you to Ben.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Mattocks Swenson to introduce you to Ben

You →Mattocks · together at L2 Ventures (2020–2026) →Ben

Ask Jamie Chen to introduce you to Ben

You →Jamie · together at LSU Health Sciences Center →Ben

Ask Sam Okafor to introduce you to Ben

You →Sam · 2 people · together at National Institute of Environmental Health Sciences (NIEHS) →Ben

Sign up to find every way you can get introduced to Ben

  • Your email: the people you already email who know Ben
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Ben
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Ben Scruggs is CEO of Altis Biosystems, where he oversees commercialization of a human intestinal platform derived from stem cells for applications in ADME assessment, toxicity, inflammation, metabolism, and epithelial repair. He is also a Partner at Hatteras Venture Partners, investing in biotechnology and life science tools companies and advising on strategy and commercialization. Scruggs serves on the boards of IMMvention Therapeutix and Veralox Therapeutics.

Contact· self-published, not guessed

Experience

  1. Hatteras Venture PartnersPartnercurrent2025 — present
  2. Hatteras Venture PartnersPrincipal2021 — 2024
  3. Hatteras Venture PartnersAssociate2017 — 2021
  4. Hatteras Venture PartnersAnalyst2017Raleigh-Durham-Chapel Hill Area
  5. Hatteras Venture PartnersHatteras Fellow2016Raleigh-Durham-Chapel Hill Area
  6. Altis BiosystemsChairman & CEOcurrent2023 — present
  7. VERALOX TherapeuticsBoard Membercurrent2021 — present
  8. IMMvention Therapeutix, Inc.Board Membercurrent2020 — present
  9. L2 VenturesManagercurrent2020 — present
  10. Tune TherapeuticsSr. Director, Strategic Initiatives2022 — 2023
  11. National Institute of Environmental Health Sciences (NIEHS)Postdoctoral Fellow2013 — 2016
  12. Washington University School of MedicinePh.D. Candidate in Molecular Cell Biology2006 — 2012
  13. Vanderbilt University Medical CenterUndergraduate research2003 — 2006
  14. National Institutes of HealthSummer Research Intern2004 — 2005
  15. LSU Health Sciences CenterSummer research intern2003
  16. LSU Health Sciences CenterScience and Medicine Academic Research Training Program2001 — 2002

Skills & more

NAMs (New Approach Methodologies)1ADME / DMPK1Intestinal permeabilityBioavailabilityCell Biology19Molecular Biology15Confocal Microscopy10Genomics5Western Blotting4qPCR3Cell Culture4Proteomics3
+11 moreVenture CapitalBoard GovernanceFundraisingBiotechnologyDue DiligenceMicroscopyImmunohistochemistryRNA biologyGene ExpressionTranscriptional RegulationLife Sciences

From Ben's professional profile.

Investments

Investor

Veralox

Per curated public sources.

Colleagues at Hatteras Venture Partners

Alston Gardner
Special Advisor at Hatteras Venture Partners
Ben Scruggs, PhD
Partner at Hatteras Venture Partners
Christy Shaffer
General Partner at Hatteras Venture Partners
Christy Shaffer, PhD
General Partner at Hatteras Venture Partners
Clay Thorp
General Partner at Hatteras Venture Partners
Declan Devens
Operations Analyst at Hatteras Venture Partners
Douglas Reed
General Partner at Hatteras Venture Partners
Douglas Reed, MD
General Partner at Hatteras Venture Partners

Network5

Christy Shaffer
General Partner at Hatteras Venture Partners
Clay Thorp
General Partner at Hatteras Venture Partners
Don Rose
Venture Partner at Hatteras Venture Partners
Fred Goldwater
Digital Health Advisor at Excelerate Health Ventures
Holden Thorp
Venture Partner at Hatteras Venture Partners

Investors connected to Ben in public investor directories — a warm-intro map.

Frequently asked questions

Who is Ben Scruggs?
Ben Scruggs is CEO of Altis Biosystems, where he oversees commercialization of a human intestinal platform derived from stem cells for applications in ADME assessment, toxicity, inflammation, metabolism, and epithelial repair. He is also a Partner at Hatteras Venture Partners, investing in biotechnology and life science tools companies and advising on strategy and commercialization. Scruggs serves on the boards of IMMvention Therapeutix and Veralox Therapeutics.
Where does Ben Scruggs work?
Ben Scruggs is Principal at Hatteras Venture Partners.
What check size does Ben Scruggs write?
Ben Scruggs typically writes checks of $100K – $5M.
What companies has Ben Scruggs invested in?
Investments tracked here include Veralox.
Where did Ben Scruggs go to school?
Ben Scruggs studied at Washington University School of Medicine in St. Louis (PhD, Molecular Cell Biology); Vanderbilt University (B.E., Biomedical Engineering); HBX | Harvard Business School (CORe: Credential of Readiness).

Founder mafias

Same school

Shared employers